Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth

Sven Gowal, Matteo de Giacomi and Jean-Yves Le Boudec
Sven Gowal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matteo de Giacomi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Yves Le Boudec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-07-0238 Published September 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • Immune response
  • Immune responses to cancer

To the Editor:

In ref. ( 1), “A validated mathematical model of cell-mediated immune response to tumor growth”, de Pillis et al. present a mathematical model describing the interactions between the immune cells, CD8+ T-lymphocytes and natural killer (NK) cells. Differential equations are used to describe tumor-immune growth, response, and interaction rates. The parameters reflect general biological quantities: most values were provided by biology literature, whereas some of them were estimated using a least-squares method and validated on mice and human real data. The authors use the results of their simulations to conclude that tumor regression is more influenced by CD8+ T cell activity than by NK cells.

We tried to reproduce the results in ref. ( 1) with the same constants, but obtained different results. We explain this by the choice of initial conditions of the model. We use, as initial conditions, the healthy steady state (i.e., absence of tumor). In contrast, we could reproduce the results in ref. ( 1) only by taking initial conditions that were not biologically plausible. This changes the conclusion about the efficacy of NK cells.

The Model

The model in ref. ( 1) is:Mathwith T(t) the tumor cell population at time t, N(t) the total level of NK cell effectiveness, and L(t) the level of tumor-specific CD8+ T cell effectiveness. Details about constants are discussed in ref. ( 1).

Initial Conditions

A natural choice for the initial conditions is the healthy state, which we now analyze. Assume that no tumor is present [T(0) = 0], thusMathHence, N(t) → Math and N(t) → 0 when t → ∞. This shows that without a tumor, the system converges to a stable state. Simulations launched with these initial conditions produce different results than those in ref. ( 1). The only way we can reproduce the original results is to choose N(0) = 0 and L(0) = 0 as initial conditions. This is not biologically plausible because NK cells are known to be always present and immediately effective against tumor (innate immune system response). The results with our initial conditions are shown in Fig. 1 , in which we also compare the original results in ref. ( 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Results of the same simulations as in ref. ( 1) with corrected initial conditions. A, response by NK and CD8+ cells to ligand-transduced vaccine using our initial conditions; B, same as in (A) but with the initial conditions in Fig. 4 (top right) from ref. ( 1); C, simulation of mouse model with anti-CD8+ antibody challenged with ligand-transduced cells; D, same as (C) but with the initial conditions in Fig. 4 (bottom right) from ref. ( 1).

In Fig. 1A, we see that NK cells alone are able to control the tumor size before CD8+ cells start destroying the tumor, contrary to what is shown in Fig. 1B. Similarly, Fig. 1C shows that, without CD8+ cells, NK cells are able to control tumors up to a size of 106 cells, whereas in Fig. 1D, they can only control tumors with a size of up to 104 cells.

Conclusion

We showed that applying biologically plausible initial conditions to the model presented in ref. ( 1) leads to a different conclusion: NK cells are by far more effective. Any potential ineffectiveness of NK cells must come from causes not present in the model.

  • ©2007 American Association for Cancer Research.

References

  1. ↵
    de Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 2005; 65: 7950–8.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Research: 67 (17)
September 2007
Volume 67, Issue 17
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
Sven Gowal, Matteo de Giacomi and Jean-Yves Le Boudec
Cancer Res September 1 2007 (67) (17) 8419-8421; DOI: 10.1158/0008-5472.CAN-07-0238

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
Sven Gowal, Matteo de Giacomi and Jean-Yves Le Boudec
Cancer Res September 1 2007 (67) (17) 8419-8421; DOI: 10.1158/0008-5472.CAN-07-0238
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • To the Editor:
    • The Model
    • Initial Conditions
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Quantifying Preexisting Resistant and Persister Populations–Response
  • Quantifying Preexisting Resistant and Persister Populations–Letter
  • Tau Mutations as a Novel Risk Factor for Cancer—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement